Codeine / Phenylephrine / Promethazine Dosage
Medically reviewed on January 15, 2018.
Applies to the following strengths: 10 mg-5 mg-6.25 mg/5 mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Cough and Nasal Congestion
Average effective dose: 5 mL orally every 4 to 6 hours as needed
Maximum dose: 30 mL (promethazine 37.5 mg; phenylephrine: 30 mg; codeine: 60 mg) in 24 hours
-Each 5 mL contains Promethazine 6.25 mg/Phenylephrine 5 mg/Codeine 10 mg.
-Liquid preparations should be measured with an accurate milliliter measuring device.
Uses: Temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.
Renal Dose Adjustments
Use with caution, especially in patients with severe renal impairment
Liver Dose Adjustments
Use with caution, especially in patients with severe hepatic impairment
Elderly: Use with caution generally starting at the lower end of the dosing range.
US BOXED WARNINGS: RESPIRATORY DEPRESSION IN CHILDREN; DEATH RELATED TO ULTRA-RAPID METABOLISM OF CODEINE TO MORPHINE and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
-The combination of promethazine hydrochloride and codeine phosphate is contraindicated in pediatric patients less than 6 years of age. Concomitant administration of promethazine products with other respiratory depressants has an association with respiratory depression, and sometimes death, in pediatric patients.
-Postmarketing cases of respiratory depression, including fatalities, have been reported with use of promethazine hydrochloride in pediatric patients less than 2 years of age. A wide range of weight-based doses of promethazine hydrochloride have resulted in respiratory depression in these patients.
-Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to CYP450 2D6 polymorphism.
-Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol.
The US FDA recommends against use of codeine-containing cough and cold medications in patients less than 18 years because it has been determined that the risks outweigh benefits.
Consult WARNINGS section for additional precautions.
US Controlled Substance: Schedule V; prescription only
Data not available
-Take orally with or without food
-Oral measuring devices should be used to ensure accuracy in dosing; a household teaspoon should not be considered an accurate measuring device
-Syrup contains 7.15% alcohol
-Protect from moisture and light
-Patients who are ultra-rapid metabolizers of codeine due to a CYP450 2D6 polymorphism, will convert codeine more rapidly and completely to morphine resulting in unexpectedly high morphine levels, which may be life-threatening.
-Codeine use is contraindicated in the postoperative period in children who have undergone tonsillectomy and/or adenoidectomy.
-The US FDA recommends against use of codeine-containing cough and cold medications in patients less than 18 years because it has been determined that the risks outweigh benefits.
-Cardiovascular: Monitor for signs of hypotension, especially in those whose blood pressure is compromised
-Respiratory: Monitor for respiratory depression
-Gastrointestinal: Monitor for constipation and decreased bowel motility in post-operative patients.
-Patients should be monitored for the development of addiction, abuse, or misuse.
-Patients should understand that codeine use can result in addiction, abuse, and misuse.
-Patients should understand risks of life-threatening respiratory depression and when this risk is greatest; patients should be aware that a genetic mutation may result in greater codeine toxicity in some patients; breastfed infants of women who have this genetic mutation are also at risk.
-This drug may cause drowsiness, dizziness, or impair thinking or motor skills; patients should avoid driving or operating machinery until adverse effects are determined.
-Patients who experience nervousness, dizziness, or sleeplessness with this drug should discontinue use.
-Concomitant use of alcohol, sedatives, and tranquilizers may increase drowsiness; patients should avoid alcohol and consult with their healthcare provider regarding concomitant use of other CNS medications.
-Patients should be cautioned to avoid prolonged sun exposure and report any involuntary muscle movement.
-Women who are breastfeeding, pregnant, or planning to become pregnant should speak to their healthcare provider before using this product.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about codeine/phenylephrine/promethazine
- Codeine/phenylephrine/promethazine Side Effects
- During Pregnancy
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- Drug class: upper respiratory combinations
- FDA Alerts (6)
- Codeine, phenylephrine, and promethazine
- Promethazine, Phenylephrine, and Codeine
- Codeine, phenylephrine, and promethazine (Advanced Reading)
Other brands: Promethazine VC with Codeine
- Promethazine Phenylephrine and Codeine (FDA)
- Promethazine, Phenylephrine, and Codeine (Wolters Kluwer)